IHC analysis revealed that advanced gastric tumors from stage III patients exhibited more robust TrkB immunoreactivity than tumors from in stage I–II or IV patients (Figure 1B, P <0.001). This evidence concerns the gene NTRK2 and gastric neoplasm.